PedAM
Pediatric Disease Annotations & Medicines
| Disease | multiple sclerosis |
| Symptom | C0026838|spasticity |
| Sentences | 58 |
| PubMedID- 20806080 | In addition, cbd has been approved for the treatment of inflammation, pain, and spasticity associated with multiple sclerosis in humans (reviewed in ). |
| PubMedID- 25121144 | Conventional drugs have only a limited impact on spasticity associated with multiple sclerosis and are rarely satisfactory. |
| PubMedID- 23642347 | The main therapeutic results were improvement on the gross motor function classification scale and in upper limb dexterity (cerebral palsy); improvement in social functioning and interaction; reductions in stress, anxiety, and loneliness (pervasive developmental disorders and mental disorders); and decreased spasticity with improved balance (multiple sclerosis, spinal cord injury, stroke). |
| PubMedID- 22739983 | Cbd has been approved to treat inflammation, pain and spasticity associated with multiple sclerosis (ms), of which demyelination and oligodendrocyte loss are hallmarks. |
| PubMedID- 25931667 | Patient-identified factors that influence spasticity in people with stroke and multiple sclerosis receiving botulinum toxin injection treatments. |
| PubMedID- 22726074 | Cannabis derivatives tetrahydrocannabinol (thc) and cannabidiol (cbd) are available as an oromucosal spray (sativex((r))), indicated as add-on treatment, for symptom improvement in patients with moderate to severe spasticity because of multiple sclerosis (ms). |
| PubMedID- 23046749 | Sativex® (gw pharma, ltd, salisbury, wiltshire, uk), is a recently authorised medicine used for the treatment of spasticity in people with multiple sclerosis, and is derived from an extract of the cannabis plant. |
| PubMedID- 22007164 | More recently, sativex® (the combination of thc and cbd) has been marketed in canada and european countries like the united kingdom and spain for the treatment of spasticity due to multiple sclerosis, and it is currently in phase iii clinical development for the treatment of cancer pain. |
| PubMedID- PMC4058662 | More recently, sativex (the combination of thc and cannabidiol) has been marketed in canada and european countries like the uk and spain for the treatment of spasticity due to multiple sclerosis, and it is currently in phase iii clinical development for the treatment of cancer pain. |
| PubMedID- 24305054 | Baclofen, a selective gabab agonist, is used clinically to treat muscle spasticity associated with multiple sclerosis, cerebral palsy, and spinal cord injury1–3. |
| PubMedID- 21878454 | A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term sativex(r) (nabiximols). |
| PubMedID- 22573509 | Some of these pharmaceuticals, such as the mouth spray sativex, have recently been approved for the treatment of spasticity in multiple sclerosis, but they are not the first and others, such as marinol or cesamet for the treatment of vomiting and nausea, and anorexia-cachexia syndrome, had already been approved. |
| PubMedID- 22878432 | During a 6-week randomised controlled trial, sativex had a clinically relevant effect on spasticity associated with multiple sclerosis (ms). |
| PubMedID- 24256407 | spasticity in patients with multiple sclerosis--clinical characteristics, treatment and quality of life. |
| PubMedID- 21456949 | Thc and cbd oromucosal spray (sativex(r)) in the management of spasticity associated with multiple sclerosis. |
| PubMedID- 25649546 | (1995) demonstrated that decreased presynaptic inhibition played a role in spasticity in people with multiple sclerosis and spinal cord injury , in spasticity due to stroke, it seems not to be a systematic contributor . |
| PubMedID- 21882460 | These include cox2-selective inhibitors (celecoxib launched 1999 for pain and inflammation), the n-type calcium channel inhibitor ziconotide (launched 2005), the triptan class of serotonin receptor subtype 1b/d agonists (sumatriptan launched early 1990s), and newer cannabinoids such as sativex, launched in canada 2005 for the treatment of pain and spasticity due to multiple sclerosis. |
| PubMedID- 22721367 | Pharmacological treatment of spasticity in multiple sclerosis. |
| PubMedID- 20307378 | A double-blind, randomized, placebo-controlled, parallel-group study of sativex, in subjects with symptoms of spasticity due to multiple sclerosis. |
| PubMedID- 22721362 | spasticity in multiple sclerosis. |
| PubMedID- 25158585 | Cannabinoid was licensed in 2012 for the treatment of spasticity associated with multiple sclerosis in finland. |
| PubMedID- 23685108 | We describe a 39-year-old man with severe lower limb spasticity due to secondary progressive multiple sclerosis that was managed with insertion of an intrathecal baclofen pump. |
| PubMedID- 23371380 | Importance and treatment of spasticity in multiple sclerosis : results of the move 1 study. |
| PubMedID- 24292503 | Objectives: to describe the current management patterns of multiple sclerosis (ms) patients with spasticity in germany and the impact of ms spasticity on quality of life (qol) and associated costs. |
| PubMedID- 26166264 | Effect of sativex on spasticity-associated symptoms in patients with multiple sclerosis. |
| PubMedID- 22586334 | Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. |
| PubMedID- 24671907 | Delta-9-tetrahydrocannabinol/cannabidiol (sativex(r)): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. |
| PubMedID- 23373525 | The meaning of spasticity to people with multiple sclerosis: what can health professionals learn. |
| PubMedID- 23072659 | Background: spasticity is common in patients with multiple sclerosis (ms) and is a major contributor to disability. |
| PubMedID- 23108552 | These can be prescribed for the amelioration of chemotherapy-induced nausea and vomiting (cesamet and marinol), stimulation of appetite (marinol) and symptomatic relief of cancer pain and/or management of neuropathic pain and spasticity in adults with multiple sclerosis (sativex). |
| PubMedID- 25623252 | The high cost of spasticity in multiple sclerosis to individuals and society. |
| PubMedID- 19863647 | Effects of intermittent theta burst stimulation on spasticity in patients with multiple sclerosis. |
| PubMedID- 20234785 | Cannabinoids such as cannabis-based medicinal extracts (cbmes) are increasingly being used in the treatment of spasticity associated with multiple sclerosis (ms). |
| PubMedID- 26409407 | Anodal transcranial direct current stimulation of motor cortex does not ameliorate spasticity in multiple sclerosis. |
| PubMedID- 24081891 | Consensus document on spasticity in patients with multiple sclerosis. |
| PubMedID- 22629287 | Most research using oral preparations has targeted neuropathic pain and spasticity associated with multiple sclerosis (ms). |
| PubMedID- 23297730 | spasticity in multiple sclerosis: results of a patient survey. |
| PubMedID- 21144973 | Background: cannabidiol, the most abundant nonpsychoactive constituent of cannabis sativa (marijuana) plant, exerts anti-inflammatory effects in various disease models and alleviates pain and spasticity associated with multiple sclerosis in humans. |
| PubMedID- 25531685 | Mobility improvement with spasticity in multiple sclerosis in europe: the move 1 eu study. |
| PubMedID- 26283920 | The gabab receptor agonist, baclofen, is used to treat muscle tightness and cramping caused by spasticity in a number of disorders including multiple sclerosis (ms), but its precise mechanism of action is unknown. |
| PubMedID- 20558502 | Meta-analysis of the efficacy and safety of sativex (nabiximols), on spasticity in people with multiple sclerosis. |
| PubMedID- 23543341 | Group exercise training for balance, functional status, spasticity, fatigue and quality of life in multiple sclerosis: a randomized controlled trial. |
| PubMedID- 23543344 | Does giving segmental muscle vibration alter the response to botulinum toxin injections in the treatment of spasticity in people with multiple sclerosis. |
| PubMedID- 24648785 | Given the therapeutic potential of cannabinoids such as δ9-thc in the management of medical conditions including neuropathic pain or spasticity due to multiple sclerosis (for a review see grant et al146), an understanding of the neural mechanisms underlying the effects of cannabis on memory function also has a wider implication beyond psychiatric disorders, as it may lead to the identification or synthesis of related molecules with the desired therapeutic effects, but without the undesired side effects. |
| PubMedID- 24115748 | This medicine, for the treatment of spasticity due to multiple sclerosis, is the first cannabis-based medicine to be approved in the uk. |
| PubMedID- 24701201 | Hd of both h-reflex and sr amplitudes in response to previous stretch of the so muscle have been compared between neurologically intact and participants with spasticity arising from multiple sclerosis or spinal cord injury (nielsen et al., 1995; grey et al., 2008). |
| PubMedID- 22133480 | spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-beta to glatiramer acetate: the escala study. |
| PubMedID- 23582109 | Comparison of the effect of baclofen and transcutaneous electrical nerve stimulation for the treatment of spasticity in multiple sclerosis. |
| PubMedID- 22536451 | Indeed this was part of the rationale behind the development of sativex®, a cannabinoid formulation containing a 1.07∶1 thc ∶ cbd dose, approved for use in various countries for the treatment of spasticity associated with multiple sclerosis. |
| PubMedID- 26103031 | Findings: use of marijuana for chronic pain, neuropathic pain, and spasticity due to multiple sclerosis is supported by high-quality evidence. |
Page: 1 2